NantCell


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

NantCell, a wholly-owned subsidiary of NantWorks, is an immuno-oncology company focused on the discovery of innovative antibody, T cell and NK cell based treatments by developing molecularly targeted therapeutics, based on the proteomic profile of the patient's tumor, independent of the cancer's anatomical type. NantCell aims to develop a pipeline of human antibodies and inhibitors of proteins which drive tumor growth and pursue Chimeric Receptor Antigen platforms in both T and NK cells. NantCel...Show all

NantCell, a wholly-owned subsidiary of NantWorks, is an immuno-oncology company focused on the discovery of innovative antibody, T cell and NK cell based treatments by developing molecularly targeted therapeutics, based on the proteomic profile of th...Show all

Company (Alive / Active)

Phone: 310-883-1300

Fax:

9920 Jefferson Blvd

Culver City, 90232
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
NantCell $241.6M Apr 14, 2017

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related NantCell Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Sequence arrangements and sequences for neoepitope presentation Mar 23, 2017 Application